<DOC>
	<DOC>NCT00959777</DOC>
	<brief_summary>The safety, tolerability, and pharmacokinetics(PK)/pharmacodynamics (PD) of DA-3031 (PEG-G-CSF) following a single dose delivered by subcutaneous (SC) injection were investigated in healthy volunteers. PK/PD of filgrastim (Dong-A) following repeated dose delivered by SC injection were investigated in healthy volunteers. PK/PD from a single dose of DA-3031 and repeated dose of filgrastim (Dong-A) were compared.</brief_summary>
	<brief_title>Pharmacokinetic/Pharmacodynamic (PK/PD) Study Evaluating DA-3031 (PEG-G-CSF) to Filgrastim (Dong-A) in Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Healthy males subjects, 2040 years inclusive weight 6075 kg inclusive and Ideal Body Weight (IBW) between 15% and +15% inclusive Written informed consent given Willing and able to comply with the requirements of the protocol Hypersensitivity to drugs(aspirin, antibiotics and so on) History or presence of any clinically significant liver or kidney disease, gastrointestinal, cardiovascular, respiratory, endocrinal, musculoskeletal, neurologic/psychiatric, hematological, oncological pathology Have a history of drug abuse, or show positive for drug abuse at urine screening Have participated in another clinical study within 2 months prior to entering inth the study Have been persistently drinking alcohol or can not stop drinking alcohol during the study Smokers whose average smoke for last 3 months is more than 10 cigarettes/day Are considered ineligible by the investigator due to clinical laboratory results or any other relevant reasons</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>